CN117729920A - 可用作myt1抑制剂的甲酰胺吡咯并吡嗪和吡啶化合物及其在治疗癌症中的用途 - Google Patents

可用作myt1抑制剂的甲酰胺吡咯并吡嗪和吡啶化合物及其在治疗癌症中的用途 Download PDF

Info

Publication number
CN117729920A
CN117729920A CN202280040614.5A CN202280040614A CN117729920A CN 117729920 A CN117729920 A CN 117729920A CN 202280040614 A CN202280040614 A CN 202280040614A CN 117729920 A CN117729920 A CN 117729920A
Authority
CN
China
Prior art keywords
inhibitor
optionally substituted
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280040614.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·福尔图尼斯
J·杨
C·伯尼尔
D·杜罗彻
N·赫斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repair Therapy Co
Mt Sinai Hospital
Original Assignee
Repair Therapy Co
Mt Sinai Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repair Therapy Co, Mt Sinai Hospital filed Critical Repair Therapy Co
Publication of CN117729920A publication Critical patent/CN117729920A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280040614.5A 2021-04-07 2022-04-07 可用作myt1抑制剂的甲酰胺吡咯并吡嗪和吡啶化合物及其在治疗癌症中的用途 Pending CN117729920A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171955P 2021-04-07 2021-04-07
US63/171,955 2021-04-07
PCT/CA2022/050536 WO2022213204A1 (en) 2021-04-07 2022-04-07 Combination therapies including myt1 inhibitors

Publications (1)

Publication Number Publication Date
CN117729920A true CN117729920A (zh) 2024-03-19

Family

ID=83544890

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280040614.5A Pending CN117729920A (zh) 2021-04-07 2022-04-07 可用作myt1抑制剂的甲酰胺吡咯并吡嗪和吡啶化合物及其在治疗癌症中的用途

Country Status (6)

Country Link
US (1) US20240207300A1 (https=)
EP (1) EP4319752A4 (https=)
JP (1) JP2024514844A (https=)
CN (1) CN117729920A (https=)
CA (1) CA3214900A1 (https=)
WO (1) WO2022213204A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435090B2 (en) 2021-10-04 2025-10-07 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
CN119451958A (zh) * 2022-07-12 2025-02-14 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
KR20250094718A (ko) * 2022-11-08 2025-06-25 제노 매니지먼트, 인크. Wee1 억제제로 암을 치료하기 위한 예측 바이오마커로서 시클린 e1 상태의 용도
WO2024104282A1 (zh) * 2022-11-14 2024-05-23 捷思英达控股有限公司 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用
EP4624471A4 (en) * 2022-11-25 2026-03-18 Shanghai Qilu Pharmaceutical Res And Development Centre Ltd PKMYT1 INHIBITOR, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION, AND ITS USE
JP2025542335A (ja) * 2022-12-22 2025-12-25 リペア セラピューティクス インコーポレイテッド Ｍｙｔ１阻害剤である２－アミノ－１－（３－ヒドロキシ－２，６－ジメチルフェニル）－５，６－ジメチル－１Ｈ－ピロロ－［２，３－ｂ］ピリジン－３－カルボキサミドを作製する方法
WO2024153249A1 (zh) * 2023-01-20 2024-07-25 杭州英创医药科技有限公司 作为pkmyt1抑制剂的化合物
WO2024160683A1 (en) * 2023-01-30 2024-08-08 Ecole Polytechnique Federale De Lausanne (Epfl) Pou5f1b inhibitors
WO2024179948A1 (en) * 2023-02-28 2024-09-06 F. Hoffmann-La Roche Ag Indazole compounds as pkmyt1 kinase inhibitors
AU2024231943A1 (en) * 2023-03-09 2025-10-16 Cancer Research Technology Limited Biarylamide derivatives and their use as pkmyt1 inhibitors
TW202444721A (zh) * 2023-05-12 2024-11-16 智擎生技製藥股份有限公司 稠合吡咯環或稠合吡啶環之化合物
CN121358735A (zh) * 2023-07-04 2026-01-16 杭州领业医药科技有限公司 Rp-6306的晶型及其制备方法和用途
WO2025040014A1 (zh) * 2023-08-18 2025-02-27 英矽智能科技知识产权有限公司 并环化合物及其制备方法和用途
IL326854A (en) * 2023-09-14 2026-04-01 Debiopharm Int Sa Combination of WEE1 inhibitor and PKMYT1 inhibitor
WO2025060975A1 (en) * 2023-09-18 2025-03-27 Insilico Medicine Ip Limited Novel compounds as pkmyt1 inhibitors and use thereof
WO2025074271A1 (en) * 2023-10-02 2025-04-10 Repare Therapeutics Inc. Myt1 inhibitors for the treatment of cancers harboring replication stress mutations
WO2025074275A1 (en) * 2023-10-02 2025-04-10 Repare Therapeutics, Inc. Combination therapies including myt1 inhibitors and wee1 inhibitors
WO2025106635A1 (en) * 2023-11-15 2025-05-22 Zeno Management, Inc. Alteration of f-box and wd repeat domain containing 7 (fbxw7) gene as a predictive biomarker for treating cancer with wee1 inhibitors
KR20250088374A (ko) * 2023-12-08 2025-06-17 인제대학교 산학협력단 Ezh2 저해제 및 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물
WO2025182927A1 (ja) * 2024-02-27 2025-09-04 中外製薬株式会社 Ｍｙｔ１阻害剤の用途
WO2025188680A1 (en) * 2024-03-04 2025-09-12 Cardiff Oncology, Inc. Use of plk1 inhibitor in combination of gemcitabine or carboplatin in treating ovarian carcinoma
WO2025237957A1 (en) * 2024-05-14 2025-11-20 Institut Curie Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor
US20260034078A1 (en) 2024-07-31 2026-02-05 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud Xpg inhibitor compounds and the use thereof in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033837A2 (en) * 1998-12-07 2000-06-15 Smithkline Beecham Corporation Myt1 kinase inhibitors
WO2016104777A1 (ja) * 2014-12-26 2016-06-30 国立大学法人九州大学 がんの処置のための方法
CN115811976A (zh) * 2020-04-01 2023-03-17 修复治疗公司 使用myt1抑制剂的方法
BR112022019611A2 (pt) * 2020-04-01 2022-11-29 Repare Therapeutics Inc Compostos, composições farmacêuticas e métodos para preparar compostos e seu uso

Also Published As

Publication number Publication date
US20240207300A1 (en) 2024-06-27
WO2022213204A1 (en) 2022-10-13
EP4319752A1 (en) 2024-02-14
CA3214900A1 (en) 2022-10-13
JP2024514844A (ja) 2024-04-03
WO2022213204A9 (en) 2023-11-16
EP4319752A4 (en) 2025-03-26

Similar Documents

Publication Publication Date Title
CN117729920A (zh) 可用作myt1抑制剂的甲酰胺吡咯并吡嗪和吡啶化合物及其在治疗癌症中的用途
EP4126879B1 (en) N-phenyl substituted indole derivatives as myt1 inhibitors for the treatment of cancer
US12435090B2 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
US20230158022A1 (en) Methods of using myt1 inhibitors
CN107922417B (zh) 蝶啶酮衍生物作为egfr抑制剂的应用
CN112724145A (zh) 用于抑制shp2活性的吡嗪衍生物
CN113474347A (zh) Mat2a的aza杂双环抑制剂和用于治疗癌症的方法
US20230142913A1 (en) Tricyclic heteroarenes, pharmaceutical compositions containing the same, and methods of using the same
JP2022510501A (ja) 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法
TW201825472A (zh) 新穎化合物類
EP3013805B1 (en) Sulfoximine substituted quinazolines and their use as mnk1 and/or mnk2 kinase inhibitors
WO2021139775A1 (zh) 吡啶酮化合物及应用
CN120712252A (zh) 包含sos1抑制剂和抗癌药物的用于治疗癌症的药物组合物
EP3858833B1 (en) Aminonorbornane derivative and manufacture method thereof and use thereof
CN119894872A (zh) 杂芳烃、含有杂芳烃的药物组合物及其使用方法
EP3568397B1 (en) Compounds and their use in the treatment of schistosomiasis
TW202220987A (zh) 經取代雜環化合物及其治療用途
EP3077383B1 (en) Sulfoximine substituted quinazolines for pharmaceutical compositions
CN116789673B (zh) 一种吡咯并嘧啶衍生物及其制备方法、药物组合物和应用
US20230348456A1 (en) Quinazolinones, pharmaceutical compositions containing the same, and methods of using the same
WO2020162471A1 (ja) ピリドン誘導体
CA3240381A1 (en) Pyrimidines and methods of their use
HK40108100A (zh) 可用作myt1抑制剂的甲酰胺吡咯并吡嗪和吡啶化合物及其在治疗癌症中的用途
CN120435458A (zh) 取代的喹啉作为改进的nf-kb诱导激酶(nik)抑制剂
EA052456B1 (ru) Соединения, фармацевтические композиции, а также способы получения соединений и их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40108100

Country of ref document: HK